RE2, Inc. Awarded Contract to Develop Exoskeleton Simulator
February 19 2014 - 8:00AM
Marketwired
RE2, Inc. Awarded Contract to Develop Exoskeleton Simulator
RE2 Partners With Ekso Bionics and Stanford to Develop the
Biomechanical Exoskeleton Simulator System
PITTSBURGH, PA--(Marketwired - Feb 19, 2014) - RE2, Inc.
announced today that the company has been awarded a Phase I Small
Business Innovation Research (SBIR) program with the U.S. Army to
develop the Biomechanical Exoskeleton Simulator System, a software
tool to assess the impact of load carriage and body-wearable
robotic devices on musculoskeletal health and performance. RE2 is
partnering with biomechanical exoskeleton experts at Ekso Bionics™
(OTCBB: EKSO) and neuromusculoskeletal simulation leader, Dr. Scott
Delp, faculty at Stanford University.
Military personnel often carry heavy loads in harsh environments
for missions or field training operations that last for extended
periods of time. Carrying heavy loads decreases physical
performance and increases the likelihood of musculoskeletal
injuries.
The goal of this SBIR program is to develop a simulation system
that can accurately model the injury risk, metabolic loading, and
the forces and the torques on the human musculoskeletal system for
soldiers carrying loads with assistance from exoskeletons. "By
directly modeling the interaction between the operator and the
exoskeleton while identifying potential injury mechanisms and
issues before large-scale deployment of the device, the simulation
system will reduce risk and enable improved design of new assistive
technologies," stated Dr. Andrew B. Mor, principal scientist for
RE2.
"The development of an exoskeleton simulator further advances
our capabilities in the field of assistive robotics," stated Jorgen
Pedersen, president and CEO of RE2. "Ultimately, this technology
will mitigate the need for costly and time consuming
experimentation with human test volunteers and reduce time to
market for emerging robotic assistive devices."
This work is supported by the US Army Medical Research and
Materiel Command under Contract No. W81XWH-14-C-0002. The
views, opinions and/or findings contained in this report are those
of the author(s) and should not be construed as an official
Department of the Army position, policy or decision unless so
designated by other documentation.
About RE2, Inc. RE2 is a leading developer of Intelligent
Modular Manipulation Systems. RE2's mission is to advance the state
of the art of mobile manipulation. RE2's development efforts are
focused on creating interoperable manipulation systems, intuitive
human robot interfaces, and advanced autonomy software for mobile
robotics. For more information, please visit www.resquared.com or
call 412.681.6382.
Media Contact: RE2 Public Relations Email Contact
412.681.6382
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024